Achieve over 98% viability and up to a 10% recovery increase in automated leukapheresis cryopreservation
Cell & Gene Therapy Insights 2026; 12(8)
10.18609/cgti.2026.106
Published: 16 September
Tech Showcase
Variability in leukapheresis starting material can erode cell recovery before cell and gene therapy manufacturing begins, and the challenge is compounded across global supply chains. Comparative process data from IntegriCell®, an automated closed cryopreservation platform, helped identify where recovery was being lost and how it could be improved.
In this interactive summary and video, Alice Bouchoms (Cryoport Systems | IntegriCell) shares multi-site data on:
✓
How total nucleated cell (TNC) count and hematocrit affected post-wash recovery
✓
5–10% increase in cell recovery following wash step optimization
✓
>98% pre-freeze and ~95% post-thaw average viability, consistent across US and EU sites
Click image above to see a taster video
Want to learn more?
View the interactive summary and video for free by clicking the link below.
